Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
doi:10.1139/cjpp-2023-0464
Our advice is always backed by medical research and tailored to fit your specific health needs
Gant, Personal Injury General: Defense Zach T
Key points: GLP-1 use: More patients are presenting for procedures while taking GLP-1RAs for diabetes or weight loss Main concern: GLP-1RAs can delay gastric emptying, which may increase aspiration risk during sedation Continue therapy: Current guidance supports continuing GLP-1RAs in patients without significant aspiration risk, using shared decision-making Assess risk factors: Recent start or dose escalation, weekly/high-dose therapy, GI symptoms, gastroparesis or other motility disorders Key takeaway: Most interventional pain procedures can be performed safely with local anesthetic alone, making conscious sedation unnecessary in many cases Conclusion: This study highlights the importance of individualized risk assessment and avoiding unnecessary sedation to improve safety in patients taking GLP-1RAs
once you begin moving, you often end up doing more
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines predispositions in GLP-1 receptor and gut-related pathway variants that may influence how your body responds to GLP-1 medications, including susceptibility to gastrointestinal side effects
